A phase 2 randomized, open-label, parallel group study to assess the immunogenicity, safety, and tolerability of Moderna mRNA-1273 vaccine administered with casirivimab+imdevimab in healthy adult volunteers

Awarded By

Contributors

Start/End

  • August 20, 2021 - February 28, 2023